Hypoparathyroidism refers to a rare endocrine disorder characterized by insufficient levels of parathyroid hormone in the body. The parathyroid glands located in the neck regulate calcium and phosphate levels in the blood by producing parathyroid hormone. Hypoparathyroidism disorder occurs when the parathyroid glands are damaged, removed or do not work properly due to various reasons like thyroid surgery, autoimmune disorders, genetic disorders. Symptoms of hypoparathyroidism include muscle spasms, seizures, abnormal sensations, facial twitching, and tingling in the fingers and around the mouth. The primary treatment for hypoparathyroidism includes calcium and vitamin D supplements to maintain appropriate calcium levels in the blood and prevent symptoms associated with low calcium. .
The hypoparathyroidism market is estimated to be valued at USD 731.1 Mn in 2024 and is expected to reach USD 1213.4 Mn by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Key Takeaways
Key players operating in the hypoparathyroidism are Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd, Amgen Inc., AbbVie Inc., and Lupin Pharmaceuticals, Inc.
The increasing prevalence of hypoparathyroidism and rising awareness about the condition among patients and physicians are fueling the demand for effective treatment options. According to the National Organization for Rare Disorders, hypoparathyroidism affects about 1 in 20,000 to 1 in 100,000 people.
Geographically, North America dominates the global hypoparathyroidism market. However, Asia Pacific region is expected to witness fastest Hypoparathyroidism Market Growth due to expanding healthcare infrastructure and increasing healthcare spending in developing countries such as India and China.
Market drivers
Increasing prevalence of hypoparathyroidism due to various factors like thyroid and parathyroid gland surgery, genetic disorders, and autoimmune disorders is a major driver for the hypoparathyroidism market growth. According to the American Society for Bone and Mineral Research, the estimated prevalence of hypoparathyroidism in post-thyroidectomy patients ranges between 0.13% and 13.8%. Further, rising awareness about symptoms and available treatment options among patients and physicians will augment the market during forecast period.
PEST Analysis
Political: The political landscape can have an impact on the hypoparathyroidism market. Government policies related to pricing and reimbursement of medicines will influence the growth of this market.
Economic: Factors like the overall economic growth, per capita income will impact spending on healthcare and hypoparathyroidism treatment. The availability of medical insurance coverage affects affordability of therapies.
Social: Increased accessibility to information has led to better awareness about hypoparathyroidism among people. Moreover, social stigma related to certain conditions is reducing which encourages seeking timely treatment.
Technological: Advancements in drug delivery mechanisms as well as diagnostic technologies help detect and manage hypoparathyroidism better. DNA testing facilitates faster diagnosis. Monitoring devices aid in tracking key biomarker levels.
The United States accounts for the largest share of the global hypoparathyroidism market in terms of value. This can be attributed to the consolidating pharmaceutical industry in the country as well as high healthcare spending. Factors such as availability of advanced treatment options and presence of major market players have further supported market growth in the region.
The Asia Pacific region is predicted to witness the fastest growth over the forecast period for the hypoparathyroidism market. This can be credited to the rising incidences of the condition coupled with improving access to diagnosis and care. Countries like China and India represent lucrative opportunities due to their huge population base and increasing investments in healthcare infrastructure and services.
Get This Report in Japanese Language: 副甲状腺機能低下症市場
Get This Report in Korean Language: 저갑상선기능저하증 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)
